Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

SNDX 01.07.2025

SERA-AI Powered Highlights
Drug:revumenib-Revuforj Revuforj® (revumenib)
Drug:axatilimab-csfr-Niktimvo Niktimvo™ (axatilimab-csfr)
Date of Upcoming Event:2025-01-14
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur SNDX Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 12.20.2024 - 8-K Current report

WALTHAM, Mass.,Jan. 7, 2025/PRNewswire/ --Syndax Pharmaceuticals(Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced thatMichael A. Metzger, Chief Executive Officer of Syndax, will present at the 43rd AnnualJ.P. Morgan Healthcare ConferenceonTuesday, January 14, 2025at10:30 a.m. PT/1:30 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website atwww.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and NiktimvoTM (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.comor follow the Company onXandLinkedIn.

Syndax Contact

Sharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827

SNDX-G

CisionView original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-43rd-annual-jp-morgan-healthcare-conference-302343500.html

SOURCESyndax Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com